COVID19, Influenza Vaccination, ACE Inhibitors, ARB, Antihistamine Allergy, Amantadine
Conditions
Brief summary
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
Detailed description
The number COVID cases would be related to hospital admissions. Among hospital admissions, the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors) would be studied. If patients that previously received the influenza vaccine or treated with ACEI, ARB, antihistamines or amantadine showed a better evolution, it would be proposed to extend vaccination and the inclusion of ACE inhibitors, ARB, antihistamines or amantadine in the treatment of infection.
Interventions
DRUGAntihistamine
No intervention is performed. We propose an observational study.
DRUGAmantadine
No intervention is performed. We propose an observational study
DRUGACEI
No intervention is performed. We propose an observational study.
DRUGARB
No intervention is performed. We propose an observational study.
OTHERInfluenza vaccine and COVID
No intervention is performed. We propose an observational study.
Sponsors
Consorci Sanitari de Terrassa
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Institut Català de la Salut
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.
Exclusion criteria
* None. * For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| hospital output | from March 1, 2020. | exitus vs hospital output |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| hospital stay | From March 1, 2020. | length of the hospital stay |
Countries
Spain
Contacts
CONTACTAnna Puigdellívol-Sánchez, Ph.D.
CONTACTMar Muñoz
PRINCIPAL_INVESTIGATORAnna Puigdellívol-Sánchez, Ph D
Consorci Sanitari de Terrassa
Outcome results
None listed